Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | TDO2 | P48775 | 4/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775591 | 0.83 | — | — | |
| SCHEMBL630549 | 0.78 | CRBN (0.43) | CRBNDDB1 | |
| SCHEMBL351324 | 0.76 | PDE7A (0.50) | CRBN | |
| SCHEMBL22422289 | 0.76 | PDE7A (0.50) | CRBN | |
| SCHEMBL11870539 | 0.76 | PDE7A (0.50) | CRBN | |
| SCHEMBL551553 | 0.76 | PDE7A (0.50) | CRBN | |
| SCHEMBL573359 | 0.74 | CRBN (0.41) | CRBNIDO1TDO2DDB1SCN9A | |
| SCHEMBL239415 | 0.74 | CRBN (0.41) | CRBNIDO1TDO2DDB1SCN9A | |
| SCHEMBL21580713 | 0.73 | CRBN (0.40) | CRBNIDO1TDO2DDB1SCN9A | |
| Ammonia Solution, Strong SCHEMBL1763719 | 0.73 | CRBN (0.40) | CRBNIDO1TDO2DDB1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | claimed |
| EP-2387573-B1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B V (NL) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| EP-2387573-A1 | 6-PHENYL-LH-IMIDAZO Ý4, 5-C¨PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | N.V. Organon (NL) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253004-A1 | RAILCAR PRIMARY SUSPENSION | KAWASAKI JUKOGYO KABUSHIKI KAISHA (JP) | 2011-10-20 | — | — | US | disclosed |
| US-8026236-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2011-09-27 | — | — | US | disclosed |
| US-7932251-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2011-04-26 | — | — | US | disclosed |
| EP-2178873-B1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | ORGANON NV (NL) | 2010-12-22 | — | — | EP | disclosed |
| US-20100184761-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON | 2010-07-22 | — | — | US | disclosed |
| WO-2010081859-A1 | 6-PHENYL-LH-IMIDAZO [4, 5-C] PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN S AND/OR CATHEPSIN K INHIBITORS | N.V. ORGANON (NL) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009010491-A1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | N.V. ORGANON (NL) | 2009-01-22 | — | — | WO | disclosed |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1806347-A1 | AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| US-6613770-B1 | Neurokinin antagonists such as 3-(4-Isopropyl-piperazin-yl-methyl)-2-phenyl-quinoline-4-carboxylic acid (1,2-dimethyl-propyl)-amide dihydrochloride, used for prophylaxis of respiratory and gastrointerstinal disorders | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-09-02 | — | — | US | disclosed |
| EP-1131294-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031038-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184761-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSB | CRBN 854/4885IDO1 1614/4885TDO2 3779/4885 |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | CRBN 1755/4885IDO1 419/4885TDO2 1510/4885 |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | GPR119, NOD1, IRS1 | CRBN 3540/4885IDO1 839/4885TDO2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.